Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 13/20 | 0.56 |
| ▸ | CA1 | P00915 | 10/20 | 0.56 |
| ▸ | CA9 | Q16790 | 9/20 | 0.56 |
| ▸ | CA12 | O43570 | 6/20 | 0.56 |
| ▸ | CA6 | P23280 | 4/20 | 0.56 |
| ▸ | CA4 | P22748 | 3/20 | 0.56 |
| ▸ | CA5A | P35218 | 3/20 | 0.56 |
| ▸ | CA7 | P43166 | 3/20 | 0.56 |
| ▸ | CA5B | Q9Y2D0 | 3/20 | 0.56 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | PTGES2 | Q9H7Z7 | 4/20 | 0.53 |
| ▸ | CA3 | P07451 | 1/20 | 0.44 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.44 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.44 |
| ▸ | LDHA | P00338 | 1/20 | 0.43 |
| ▸ | CDK2 | P24941 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29520231 | 1.00 | CA2 (0.56) | CA2CA1CA9CA12CA6 | |
| Hydrochloric Acid SCHEMBL7460198 | 0.98 | CA2 (0.54) | CA2CA1CA9CA12CA6 | |
| Hydrochloric Acid SCHEMBL21326134 | 0.98 | CA2 (0.54) | CA2CA1CA9CA12CA6 | |
| Formic Acid SCHEMBL6027486 | 0.89 | CA1 (0.47) | CA2CA1CA9CA12CA6 | |
| SCHEMBL2568298 | 0.82 | ALOX5AP (0.49) | CA2CA1CA9CA12CA6 | |
| SCHEMBL2051439 | 0.82 | NFE2L2 (0.43) | — | |
| SCHEMBL789494 | 0.81 | PTGES2 (0.64) | CA2CA1CA9CA12CA6 | |
| SCHEMBL30307782 | 0.81 | PTGES2 (0.64) | CA2CA1CA9CA12CA6 | |
| SCHEMBL202947 | 0.81 | CA2 (0.70) | CA2CA1CA9CA12CA6 | |
| Hydrochloric Acid SCHEMBL9955460 | 0.79 | PTGES2 (0.62) | CA2CA1CA9CA12CA6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1360 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4593598-A1 | STORAGE-STABLE COMPOSITIONS INCLUDING BIXLOZONE AND BEFLUBUTAMID | FMC Corporation (US) | 2025-08-06 | — | — | EP | claimed |
| US-12331026-B2 | Sulfonamido derivatives as cyclin-dependent kinase 2 inhibitors | NIKANG THERAPEUTICS, INC. (US) | 2025-06-17 | — | — | US | claimed |
| CN-119219810-A | Ionic polymer and preparation method and application thereof | 佛山绿动氢能科技有限公司 | 2024-12-31 | — | — | CN | claimed |
| CN-118507836-B | Electrolyte for secondary lithium metal battery | 深圳欣界能源科技有限公司 | 2024-09-17 | — | — | CN | claimed |
| CN-118507836-A | Electrolyte for secondary lithium metal battery | 深圳欣界能源科技有限公司 | 2024-08-16 | — | — | CN | claimed |
| CN-113795254-B | Pyrazolopyridine compounds for IRE1 inhibition | 奥普提卡拉公司 | 2024-08-09 | — | — | CN | claimed |
| US-20240262801-A1 | COMPOUNDS HAVING 5-(2-FLUORO-6-HYDROXYPHENYL)-1,2,5-THIADIAZOLIDIN-3-ONE 1,1-DIOXIDE AS INHIBITORS OF PROTEIN KINASE PHOSPHATASE ENZYMES | MONDEGO BIO, LDA. (PT) | 2024-08-08 | — | — | US | claimed |
| CN-118324773-A | Rhodamine derivative and preparation method and application thereof | 陕西师范大学 | 2024-07-12 | — | — | CN | claimed |
| WO-2024115549-A1 | ARYL- AND HETEROARYL-SULFONAMIDE DERIVATIVES AS CCR8 MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2024-06-06 | — | — | WO | claimed |
| WO-2024073019-A1 | STORAGE-STABLE COMPOSITIONS INCLUDING BIXLOZONE AND B EFLUB UT AMID | FMC CORPORATION (US) | 2024-04-04 | — | — | WO | claimed |
| WO-1995020585-A1 | DIASTEREOSELECTIVE PROCESS LEADING TO A KEY INTERMEDIATE FOR THE PREPARATION OF FLUORINATED REVERSE TRANSCRIPTASE INHIBITORS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1995-08-03 | — | — | WO | claimed |
| EP-0447013-B1 | Fluorobenzene sulphonamides | SCHERING AG (DE) | 1994-08-03 | — | — | EP | claimed |
| CN-1090279-A | Be used for the treatment of HIV and other retroviral pyran-2-ones and 5,6-dihydropyrane-2-ketone | UPJOHN CO (US) | 1994-08-03 | — | — | CN | claimed |
| EP-0420815-B1 | Process for the preparation of 2-(2-haloethylthio)-phenylsulfonamides | CIBA GEIGY AG (CH) | 1994-01-19 | — | — | EP | claimed |
| US-5210290-A | NMR diagnostic aid | SCHERING AKTIENGESELLSCHAFT (DE) | 1993-05-11 | — | — | US | claimed |
| US-5166430-A | PROCESS FOR THE PREPARATION OF 2-(2-HALOGENOETHYLTHIO)-PHENYLSULFONAMIDES | CIBA-GEIGY CORPORATION (US) | 1992-11-24 | — | — | US | claimed |
| EP-0447013-A1 | Fluorobenzene sulphonamides | SCHERING AKTIENGESELLSCHAFT (DE) | 1991-09-18 | — | — | EP | claimed |
| EP-0420815-A1 | Process for the preparation of 2-(2-haloethylthio)-phenylsulfonamides | CIBA-GEIGY AG (CH) | 1991-04-03 | — | — | EP | claimed |
| EP-0132230-B1 | PROCESS FOR THE PREPARATION OF SULFONYL UREA | CIBA-GEIGY AG (CH) | 1988-10-05 | — | — | EP | claimed |
| EP-0132230-A2 | Process for the preparation of sulfonyl urea | CIBA-GEIGY AG (CH) | 1985-01-23 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240262801-A1 | COMPOUNDS HAVING 5-(2-FLUORO-6-HYDROXYPHENYL)-1,2,5-THIADIAZOLIDIN-3-ONE 1,1-DIOXIDE AS INHIBITORS OF PROTEIN KINASE PHOSPHATASE ENZYMES | PPM1A, TH, PPM1G | CA2 588/4885CA1 2273/4885CA9 1552/4885 |
| US-12331026-B2 | Sulfonamido derivatives as cyclin-dependent kinase 2 inhibitors | CDK2, CCNK, CCNI | CA2 2801/4885CA1 3540/4885CA9 3000/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.